A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
PHASE3CompletedINTERVENTIONAL
Enrollment
375
Participants
Timeline
Start Date
December 31, 2001
Study Completion Date
September 30, 2003
Conditions
Attention Deficit and Disruptive Behavior Disorders
Interventions
DRUG
risperidone
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00236444 - A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders | Biotech Hunter | Biotech Hunter